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Research
Several polyether ionophores, including
A23187, ionomycin, monensin, and nigericin,
have been shown to transport lead ions (Pb2+)
across phospholipid bilayers and to form sta-
ble complexes with Pb2+ in homogeneous
solution (Erdahl et al. 2000; Hamidinia et al.
2002, 2004). Among this group, the order of
transport activity is ionomycin > nigericin
> monensin > A23187, whereas the order of
selectivity, compared with other divalent
cations, is nigericin > monensin > ionomycin
> A23187. Ionomycin can be used to load
cultured cells and to deplete them of Pb2+
(Erdahl et al. 2000), and effects of monensin
on Pb dynamics in rats have also been investi-
gated (Hamidinia et al. 2002). In the latter
area it was found that simultaneous adminis-
tration of monensin in feed and Pb2+ in
drinking water lowers the prevailing concen-
tration of Pb in blood and decreases the accu-
mulation of Pb in several soft tissues and in
bone. Feeding monensin after a period of Pb2+
administration was furthermore effective at
accelerating the clearance of Pb from brain,
liver, kidney and bone, with the monensin-
related increment being found in feces, as
opposed to the Pb excreted spontaneously,
which included a component found in urine
(Hamidinia et al. 2002).
The actions of monensin on Pb dynamics
in rats suggest the possibility of using
ionophores in the treatment of human Pb
intoxication. At present, the ongoing and
widespread problem of Pb intoxication is
treated ﬁrst by removing the individual from
the Pb-contaminated environment and there-
after by administering a Pb2+ chelating agent.
meso-Dimercaptosuccinic acid (DMSA) is the
most commonly used agent at present, in part
because it can be administered orally and is
well tolerated (Cory-Slechta 1988; Graziano
et al. 1985). DMSA is a water-soluble com-
pound that forms a strong complex with Pb2+
in blood, which is thereafter secreted via the
kidney. EDTA and other chelating agents are
used in a similar way to treat Pb intoxication
(Goyer et al. 1995; Llobet et al. 1990). In all
cases, several cycles of chelator administration
given over a period of months are required to
produce an adequate and durable reduction of
Pb in blood. This is because the blood pool is
equilibrated with Pb in other internal com-
partments, such that a blood pool is reestab-
lished as Pb is mobilized from the other
compartments after a cycle of chelator admin-
istration (Graziano 1986, 1993; Graziano et al.
1985, 1988). The repetitive treatments and
extended time frames are problematic, particu-
larly when treating children, because impor-
tant aspects of Pb toxicity arise to a greater
degree if Pb is present before development is
completed. The propensity of Pb to lower IQ
(intelligence quotient) and otherwise interfere
with functions of the central nervous system is
perhaps the most important of these aspects
(Goyer 1993). An uneven effectiveness of
water-soluble chelators at removing Pb from
particular organs is another problem with
existing protocols for the treatment of Pb
intoxication, with bone (Castellino and Aloj
1964; Cory-Slechta 1988; Gerhardsson et al.
1999; Smith et al. 2000) and brain (Cremin
et al. 1999; Seaton et al. 1999; Smith et al.
1998) being particularly difﬁcult to free of the
accumulated cation. In addition, chelators can
provoke an undesirable redistribution of Pb
among soft tissues and between bone and soft
tissues (Cory-Slechta et al. 1987).
Within this context of less than ideal treat-
ments for Pb intoxication and the recent dis-
covery that several carboxylic acid ionophores
transport Pb2+ with high specificity, we are
seeking to determine if some of these com-
pounds might be used together with the tradi-
tional chelators to improve the effectiveness of
existing treatment protocols. The present
report describes the effectiveness of coadminis-
tering monensin and DMSA in this regard,
using rats as an experimental model.
Materials and Methods
Treatment of experimental animals. We used
male Sprague-Dawley rats throughout the
study. They were treated humanely and with
regard to the alleviation of suffering. The rats
were housed at the College of Medicine, Ohio
State University, in animal facilities approved
by the Association for Accreditation of
Laboratory Animal Care. A 12-hr light/dark
cycle, dual housing in plastic cages, and con-
ditions of constant temperature and humidity
were employed. We allowed 1 week for
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Among divalent cations, the ionophore monensin shows high activity and selectivity for the trans-
port of lead ions (Pb2+) across phospholipid membranes. When coadministered to rats that were
receiving meso-dimercaptosuccinate for treatment of Pb intoxication, monensin significantly
increased the amount of Pb removed from femur, brain, and heart. It showed a tendency to increase
Pb removal from liver and kidney but had no effect of this type in skeletal muscle. Tissue levels of
several physiologic (calcium, cobalt, copper, iron, magnesium, manganese, molybdenum, zinc) and
nonphysiologic (arsenic, cadmium, chromium, nickel, strontium) elements were also determined
after the application of these compounds. Among the physiologic elements, a number of signiﬁcant
changes were seen, including both rising and falling values. The size of these changes was typically
around 20% compared with control values, with the largest examples seen in femur. These changes
often tended to reverse those of similar size that had occurred during Pb administration. Among the
nonphysiologic elements, which were present in trace amounts, the changes were smaller in number
but larger in size. None of these changes appears likely to be signiﬁcant in terms of toxicity, and
there were no signs of overt toxicity under any of the conditions employed. Monensin may act by
cotransporting Pb2+ and OH– ions out of cells, in exchange for external sodium ions. The net effect
would be to shuttle intracellular Pb2+ to extracellular dimercaptosuccinic acid thereby enhancing its
effectiveness. Thus, monensin may be useful for the treatment of Pb intoxication when applied in
combination with hydrophilic Pb2+ chelators. Key words: chelation therapy, DMSA, heavy metal
intoxication, ICP mass spectroscopy, ionophores, monensin, Pb, Pb2+ transport, trace metal cations.
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[Online 29 September 2005]acclimation before the experimental protocol
began. During this period rats were fed a stan-
dard laboratory chow, whereas the AIN-93M
diet containing 0.5% calcium (normal chow;
Harlan Teklad, Madison, WI) was employed
thereafter. During the administration of Pb2+
and/or monensin and DMSA, water and feed
were provided ad libitum, and records of con-
sumption were maintained together with
periodic measurements of body weight.
Initially the rats weighed 245–255 g. They
were divided into ﬁve groups of eight, and the
administration of Pb2+ was begun. It was pro-
vided at 100 ppm in the drinking water
(0.48 mM) and was in the form of Pb(acetate)2.
The water was rendered slightly acidic with
acetic acid to prevent the precipitation of
PbCO3 (lead carbonate) (Bogden et al. 1995).
As a point of reference, after several days this
regimen produces a circulating Pb level of
1.1 µM in rats (22 µg/dL) (Hamidinia et al.
2002), which is higher by about a factor of 2
than the value of 0.5 µM (10 µg/dL), which is
often taken to be the toxic threshold for Pb in
children.
After 3 weeks, one group of rats was sacri-
ﬁced to determine the Pb content of organs at
that time (the Pb-loaded group), whereas the
remaining groups thereafter received water that
did not contain Pb2+. One of these groups
received the normal chow (no-treatment
group), another received this chow containing
100 ppm monensin (monensin group), a third
group received normal chow and DMSA
administered by oral gavage (DMSA group),
and a ﬁnal group received the chow containing
monensin and DMSA delivered by oral gavage
(monensin plus DMSA group). When admin-
istered, the 50 mg/kg dose of DMSA was given
every other day. The solution volume adminis-
tered varied between approximately 0.25 and
0.45 mL as body weight increased so as to
maintain the prescribed dose. The DMSA
solution was freshly prepared by dissolving the
compound in 5% NaHCO3 (sodium bicar-
bonate). All treatments were continued for
3 weeks beyond the time when the administra-
tion of Pb2+ had been discontinued. The rats
were then sacriﬁced by the injection of excess
Nembutal (Abbott Laboratories, North
Chicago, IL) and were subsequently perfused
brieﬂy with HEPES-buffered 0.9% NaCl, via
the left ventricle, to remove blood from the
organs. After this, organs and tissues of interest
were removed and stored at –20°C.
Determination of Pb and other elements
by inductively coupled plasma mass spec-
troscopy. All aspects of the analytical proce-
dures were conducted in laminar ﬂow hoods
within the Microscopic and Chemical Analysis
Research Center at Ohio State University.
The frozen organs were first thawed and
weighed and were then digested in 5.00 mL of
trace-metal–grade concentrated nitric acid.
One intact kidney, the entire brain, the entire
heart, and the left femur from each animal
were analyzed. For liver, a portion of the right
lateral lobe weighing approximately 2 g was
analyzed, whereas for muscle it was a similar-
sized portion of the left biceps femoris.
Digestion was conducted in acid-cleaned
quartz vials that were contained in a Teflon
liner that was itself contained in a closed high-
pressure vessel (Milestone Inc). The Teflon
liners contained 10 mL of a 6% H2O2 solu-
tion, in which the quartz vial was partially
immersed, so as to minimize the rise in inter-
nal pressure that occurs as digestion proceeds.
Samples were heated to 180°C in a microwave
apparatus (Ethos Plus; Milestone Inc.,
Shelton, CT). Temperature programming
provided for a linear rise to that value over a
10-min period, a holding period of 10 min,
and a 15-min cool-down period. Sample
blanks containing no tissue were generated in
the same way, as were occasional tissue sam-
ples that were spiked with gallium (used to
estimate overall recovery from the procedure).
After digestion, the samples were transferred
quantitatively to Nalgene LDPE Boston
round bottles (Fisher Scientific, Pittsburgh,
PA), diluted to 50.0 mL with NANOpure
water (Barnstead/Thermolyne, Dubuque, IA),
and then stored at room temperature.
Subsequent steps were carried out within
1 month. A cocktail of three internal standards
(bismuth, scandium, and rhodium) made from
CPI International (Santa Rosa, CA) peak per-
formance standards was added to each sample
(100 µL in 10.0 mL) so as to give a 10 ppb
concentration of each standard. The signals
arising from these standards were used to cor-
rect data for variations in instrument perfor-
mance that occur while a set of samples is
being analyzed. A set of calibration standards,
similar in composition to the unknown sam-
ples, was prepared for each of the six tissues
and used to convert data output from the
instrument into units of concentration. These
were prepared using SPEX Certi Prep
(Metuchen, NJ) multielement standards with
appropriate adjustments made using single-
element standards obtained from CPI
International. The samples were analyzed using
a Thermo Finnigan magnetic sector induc-
tively coupled plasma (ICP) mass spectrometer
(Thermo Electron Corporation, Waltham,
MA), which is capable of resolutions > 0.005
atomic mass units. The data were expressed
ﬁrst in units of parts per billion and were sub-
sequently converted to units of nanomoles per
gram wet weight of tissue. Replicate analysis of
single samples showed that deviation arising
from analysis per se was on the order of ± 2%,
whereas overall recovery of unknowns was
approximately 98–101%. Values obtained
from sample blanks and standard solution sam-
ples that had been carried through the entire
procedure showed that potential errors arising
from contamination in reagents, leaching/
absorption of materials from labware, and so
on, could be ignored for most elements.
Nevertheless, duplicate blanks were run with
each set of samples, and the values obtained
were subtracted from the standard and experi-
mental values during data analysis.
Pb levels in the various tissues were
expressed as means ± SE and thereafter by the
percentage change in mean values. Compari-
sons between groups were made using
Student’s t-test with differences reported as sig-
niﬁcant for p-values < 0.05. For elements other
than Pb, we asked if mean values differed
between treatment groups, and the two-tailed
test was employed accordingly. In the case of
Pb, previous work indicated that all treatments
would enhance depletion and would not be
expected to elevate the levels observed.
According, when analyzing the Pb data, we
asked if treatment in question lowered Pb, rela-
tive to the appropriate control, and the one-
tailed test was employed (Christenson and
Stoop 1986).
Results
Levels of Pb and other elements after Pb
administration. Monensin is highly selective
for the transport of Pb2+, compared with
other divalent cations (Hamidinia et al.
2002), and this is one of its characteristics
that led us to test this ionophore for possible
use in conjunction with DMSA for the treat-
ment of Pb intoxication. That is to say, it
seemed possible that monensin might aid in
the delivery of intracellular Pb2+ to the circu-
lating chelator without greatly perturbing the
intracellular level of other cations. On the
other hand, the available selectivity data were
obtained using a model transport system
based on phospholipid vesicles and did not
include all cations of possible interest. Thus,
it was not clear initially to what extent the
selectivity for Pb2+ would manifest in vivo, or
if cations having a physiologic role, but not
yet considered in terms of selectivity, might
also be perturbed. Accordingly, we examined
the tissue levels of several physiologic ele-
ments (Ca, cobalt, copper, iron, manganese,
magnesium, molybdenum, zinc) using ICP
mass spectrometry as the detection modality.
We also examined levels of several elements
having no physiologic role (arsenic, cadmium,
chromium, nickel, strontium) to determine if
the ionophores actions are specific for Pb
among a known group of potential toxins.
In Table 1 we compare the endogenous
levels of these cations as reported by Naveh
et al. (1987) with those we found at the end of
the 3-week Pb loading period. As expected, Pb
rose markedly in all organs examined, but there
were large differences in the absolute levels
attained. Specifically, the order of Pb levels
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> heart > skeletal muscle, with the highest
value exceeding the lowest one by approxi-
mately 2.5 × 103. These ﬁndings are similar to
those reported by others (Bogden et al. 1992;
Han et al. 1996; Naveh et al. 1987).
Among the other elements considered,
comparisons were possible for Ca, Cu, Fe, Mg,
Mn, and Zn, but not for Co, Mo, As, Cd, Cr,
Ni, and Sr, because the reference study did not
include data for the latter group. Among the
former group, three large variations were seen:
the level of Ca in kidney and the levels of Cu
and Mn in femur. In all three cases, the values
reported here are about 10% of the reference
values, and the differences are statistically sig-
nificant. Although there are several possible
reasons for variations of this magnitude, as fur-
ther considered in the “Discussion,” we doubt
that they reﬂect authentic effects of Pb admin-
istration and have used our present values
when interpreting other aspects of the data.
Among the other organs and elements consid-
ered, variations were much smaller. Reference
values for Fe in kidney and Mn in skeletal
muscle are higher than what we found after Pb
loading, by about a factor of 2, and these dif-
ferences were also statistically significant.
Regarding the other variations, many were not
significantly different, whereas others were,
even when the extent of variation was quite
small (Table 1).
Depletion of previously accumulated Pb.
To express the relative effectiveness of the four
treatments that were applied after the period of
Pb administration, we calculated the fraction
of the Pb loaded value that remained when the
treatment period was complete (3 weeks) and
compared these values with each other and
with the endogenous values. Results are shown
graphically and numerically in Figure 1. Two
subsets are apparent among the six tissues
examined: kidney, liver, and skeletal muscle
compared with heart, brain, and femur. For
those in the ﬁrst subset, the mean Pb level fell
dramatically simply in response to halting its
administration, and these were fully signiﬁcant
declines compared with the levels that existed
at the end of the loading period (Figure 1). For
this subset, monensin alone did not alter the
values signiﬁcantly, compared with withdrawal
alone, whereas the further decrease produced
by DMSA was signiﬁcant in kidney and liver.
The former result might not be expected,
whereas the latter was expected, based on pre-
vious reports (Cory-Slechta 1988; Hamidinia
et al. 2002; Jones et al. 1997; Pappas et al.
1995). Regarding monensin used together
with DMSA, the mean values in kidney and
liver were lower than those produced by
DMSA alone, but the p-values (0.08 in kidney,
0.14 in liver) fell short of the usual threshold of
signiﬁcance (0.05).
For the other subset of tissues (heart, brain,
and femur), halting administration alone did
not signiﬁcantly lower the level of Pb during
the 3-week test period. Compared with the val-
ues obtained by withdrawal, the effects of
monensin alone were again not significant,
except in the case of heart, where the ionophore
did produce a lower value. Regarding DMSA
alone, this treatment lowered Pb in heart and
brain but did not decrease Pb in bone, again,
as might be expected (Cory-Slechta 1988;
Gerhardsson et al. 1999; Jones et al. 1997;
Smith et al. 2000). Of greater interest, in all
three tissues, monensin plus DMSA lowered
mean Pb values more noticeably than was seen
in the other tissues, compared with the effect
of DMSA alone, and these differences were sta-
tistically signiﬁcant (Figure 1). Furthermore,
the decrease produced by monensin plus
DMSA in bone was signiﬁcant compared with
withdrawal alone, and this was also true in the
ﬁve other tissues (Figure 1).
Effects of monensin alone on the levels of
other elements. Regarding the other elements,
data are presented in Figures 2–14, which are
in the same format used for Figure 1. Given
that we are primarily interested in determining
if monensin might be useful in the treatment
of Pb intoxication, we focus ﬁrst on whether or
not the ionophore given alone perturbs physio-
logic elements. This point is of interest because
such perturbations might lead to secondary
forms of toxicity. Regarding Ca, monensin
alone increased the level in heart by approxi-
mately 24%, compared with rats that received
no treatment for accumulated Pb, but had no
signiﬁcant effect in the other tissues (Figure 2).
By the same comparison, Co was decreased in
kidney, heart, and brain, but in the no-treat-
ment group Co fell during the 3-week period
after Pb administration had ended (Figure 3).
Thus, the 25–30% increases in Co produced
by monensin were tending to reverse that ini-
tial decline and might therefore be viewed as
advantageous. Cu was increased in kidney and
brain, decreased slightly in liver and skeletal
muscle, and was not changed signiﬁcantly in
heart and femur (Figure 4). Fe rose modestly
in heart and brain but was not perturbed sig-
niﬁcantly elsewhere (Figure 5). Mg was altered
only in heart (Figure 6), and Mn in liver, heart,
and brain (Figure 7); these were all modest
variations of around 15% or less. Changes in
Mo and Zn were similarly small (Figures 8
and 9), except for the Mo level in femur,
which decreased by 70% (Figure 8).
Among the nonphysiologic elements
(Figures 10–14), the only statistically signiﬁcant
effect produced by monensin alone was in
Hamidinia et al.
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Table 1. Effects of Pb administration on the concentrations (nmol/g) of selected elements in rat tissues.
Tissue
Element Kidney Liver Skeletal muscle Heart Brain Femur
Pb 29.8* 5.77* 0.073* 0.163* 1.19* 203*
0.20 0.20 ND 0.005 0.05 ND
Physiologic
Ca 897* 574 1,318* 522* 2,418 4,025,000*
12,775 669 1,193 903 1,327 3,220,000
Co 1.24 0.352 0.025 0.523 0.093 0.130
NR NR NR NR NR NR
Cu 62.1* 51.1 13.6 101* 38.7* 5.29*
96.9 59.2 14.0 78.4 33.4 45.5
Fe 524* 1,534* 133* 1,049 239* 771
1,112 1,003 191 1,010 315 702
Mg 6,627 8,203* 10,028 8,885* 6,561* 117,300
7,365 6,665 9,998 8,023 6,048 91,750
Mn 13.1* 32.0* 1.02* 7.34* 7.12 6.44*
19.8 37.3 2.40 10.32 8.83 52.8
Mo 2.21 4.10 0.083 0.492 0.299 0.187
NR NR NR NR NR NR
Zn 295 472* 162* 315* 247* 1,844
327 329 284 246 180 1,743
Nonphysiologic
As 0.035 0.444 0.121 0.437 0.071 0.207
NR NR NR NR NR NR
Cr 0.012 0.004 0.033 0.886 0.066 ND
NR NR NR NR NR NR
Cd 0.082 0.062 0.003 0.005 0.005 0.006
NR NR NR NR NR NR
Ni 0.070 0.029 0.097 0.420 0.080 ND
NR NR NR NR NR NR
Sr 0.088 0.061 0.313 0.110 0.277 56.3
NR NR NR NR NR NR
Abbreviations: ND, not detected in this study; NR, not reported. The upper value for each element is from the present study
and was determined after the rats had been given 100 ppm Pb2+ in their drinking water for 3 weeks (see “Materials and
Methods”). The lower value for each element is from the literature and was determined using rats that had not been given
Pb: values for Pb are from Hamidinia et al. (2002), and values for the other elements are from Naveh et al. (1987).
*Values obtained during this study that are statistically different (p < 0.05) from the corresponding literature value. heart, where the trace level of As rose by
approximately 24% (Figure 10).
Perturbations produced by monensin in
DMSA-treated rats. Because Figure 1 indicates
that monensin plus DMSA is more effective at
depleting Pb than either agent used alone, it is
also of interest to determine if the two agents
used together perturb other elements more so
than does DMSA alone and to examine per-
turbations produced by the combination of
compounds compared with no treatment.
Considering the former comparison ﬁrst, and
for the physiologic elements, monensin altered
the levels of Ca, Co, Cu, Fe, and Zn in one or
more tissues, more so than did DMSA alone,
whereas the levels Mg, Mn, and Mo were not
affected statistically (Figures 2–9). Among the
changes of this type, all were small (on the
order of < 15%), except for the level of Co in
femur, which increased by 53% (Figure 3).
Furthermore, the directions of these changes
were such that they tended to reverse changes
that arose from DMSA alone and thus might
be viewed as beneﬁcial. This is with the excep-
tion of Zn in skeletal muscle and heart
(Figure 9), which was perturbed to a greater
extent by monensin plus DMSA than it was by
DMSA alone, although the effects were small
(+16% and –10%, respectively).
Considering the nonphysiologic elements,
monensin plus DMSA increased Ni substan-
tially in liver, skeletal muscle, and heart,
compared with DMSA alone (Figure 13), and
likewise decreased Sr in kidney and heart
(Figure 14). The changes in Sr were in the
direction that corrected a perturbation pro-
duced by DMSA alone, but this was not true
with Ni.
Perturbations produced by monensin plus
DMSA compared with no treatment. Within
this last area of interest, and among the physi-
ologic elements, monensin plus DMSA pro-
duced a change in one or more tissues in all
cases except Ca. Co rose in kidney, heart, and
femur, but these changes were again tending
to reverse declines that otherwise occurred in
rats that were not treated (Figure 3). Cu fell
modestly in liver, heart, and brain; Fe rose in
liver and femur, whereas Zn was altered in
liver, skeletal muscle, and femur (Figures 7–9).
All of these changes were again small, with the
exception of Mo in femur, where the increase
was 62%.
Considering the nonphysiologic elements
(Figures 10–14), significant changes were
confined to Cr and Ni, which were both
increased in liver (Figures 12 and 13).
Effects of treatment on other parameters.
Regarding macroscopic effects of the treatment
strategies investigated, there was no indication
that the rats were differently stressed, as indi-
cated by their behavior, activity level, general
appearance, and the macroscopic appearance
of internal structures seen during dissection.
Records of weight gain throughout the experi-
mental period are shown in Figure 15. During
the period of Pb administration, when all rats
were maintained in the same way, the per ani-
mal average weight of the ﬁve groups diverged
such that there was a 25 g range in this para-
meter at the time that Pb was withdrawn.
Comparing the no-treatment and the mon-
ensin-alone groups showed no signiﬁcant dif-
ference in the subsequent rate of weight gain
(Figure 15). For the rats receiving DMSA or
DMSA plus monensin, weight gain lagged
initially but then returned to a rate that was
similar to that seen in the no-treatment or the
monensin-alone groups. An unpleasant odor
of the dimercaptide and gavage-related irrita-
tion of the gastrointestinal tract may have
contributed to these lags in weight gain by
discouraging eating.
Discussion
The results of the present study demonstrate
that monensin plus DMSA is more effective
than DMSA alone in terms of depleting rats of
previously accumulated Pb, and that the com-
bination of agents is effective in all organs/
tissues examined. Comparing the agents used
in combination with DMSA alone, monensin
signiﬁcantly improved the outcome in heart,
brain, and femur and showed a tendency to do
this in kidney and liver. The improved clear-
ance seen in heart, brain, and femur is notable
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Figure 1. (A) Fractional changes (+ SE) in tissue levels of Pb produced by selected
treatments. Rats were treated as described in “Materials and Methods.” Pb levels
observed for the Pb-loaded group are presented in Table 1; values for the Pb-
loaded group were set to 1.0 to aid in normalizing values of other treatment groups.
(B) Percent changes in mean values calculated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
Figure 2. (A) Fractional changes (+ SE) in tissue levels of Ca occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A).
*Statistically signiﬁcant (p < 0.05).
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Figure 3. (A) Fractional changes (+ SE) in tissue levels of Co occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
Figure 4. (A) Fractional changes (+ SE) in tissue levels of Cu occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
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Figure 5. (A) Fractional changes (+ SE) in tissue levels of Fe occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A).
*Statistically signiﬁcant (p < 0.05). 
Figure 6. (A) Fractional changes (+ SE) in tissue levels of Mg occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A).
*Statistically signiﬁcant (p < 0.05).
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Loaded No treatment Monensin DMSA DMSA + monensin
Mg
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded –31.8* –37.7* +12.2 –22.8* –17.7* –57.3*
Monensin vs. no treatment +35.1* +8.3 +13.2 +26.6* +23.3* +14.5
DMSA vs. no treatment +15.1 –6.8 –22.3 +10.4 +6.1 +14.4
Monensin + DMSA vs. DMSA +28.5 +25.4 +13.5 +17.5* +8.3* +52.7*
Monensin + DMSA vs.  +48.0* +16.9 –11.8 +29.6* +14.9* +74.7*
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +28.2* +13.2* +0.2 +10.1 –0.5 +54.4
Monensin vs. no treatment +19.3* –7.0* –9.3* +1.0 +11.3* –24.7
DMSA vs. no treatment –2.0 –11.8* –10.2* –2.7 –6.6 –16.6
Monensin + DMSA vs. DMSA –6.9 +5.9 +2.9 –13.1* –1.2 –2.5
Monensin + DMSA vs.  –8.8 –6.6* –7.6 –15.5* –7.7* –18.7
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +26.0* +12.8 +3.2 +8.3 –5.8 +18.6*
Monensin vs. no treatment –3.0 –2.5 –4.4 +15.7* +17.9* +6.2
DMSA vs. no treatment +3.8 +16.4 +0.3 +13.3* +3.9 +19.1*
Monensin + DMSA vs. DMSA –10.3 +5.4 +2.1 –9.2* –5.8 +11.0
Monensin + DMSA vs.  –6.9 +22.7* +2.4 +2.8 –2.1 +32.1*
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded –6.9 +3.5 +12.4* –1.6 –5.9* 0
Monensin vs. no treatment +7.5 –6.2 +1.9 +9.5* +4.1 +5.5
DMSA vs. no treatment +8.1 –9.7* –0.5 +1.9 –10.3* +3.1
Monensin + DMSA vs. DMSA +3.1 +4.2 –1.8 –2.1 –6.2 +3.7
Monensin + DMSA vs.  +11.4 –5.9 –2.2 –0.3 –15.8* +6.9*
no treatment
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Figure 7. (A) Fractional changes (+ SE) in tissue levels of Mn occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
Figure 8. (A) Fractional changes (+ SE) in tissue levels of Mo occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
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Figure 9. (A) Fractional changes (+ SE) in tissue levels of Zn occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
Figure 10. (A) Fractional changes (+ SE) in tissue levels of As occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05).
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Loaded No treatment Monensin DMSA DMSA + monensin
As
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded –4.6 +5.8 –7.6 +0.2 –2.4 –5.1
Monensin vs. no treatment +4.9 –10.8* –5.0 +7.5* +6.7* –2.0
DMSA vs. no treatment +4.2 –6.3 –4.0 +1.1 –2.1 –2.4
Monensin + DMSA vs. DMSA +1.6 +5.5 +0.3 –2.8 –2.5 +3.6
Monensin + DMSA vs.  +5.8 –1.2 –3.7 –1.7 –4.6* +1.2
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +12.5* +25.9* +11.2 –3.3 –1.3 –17.6
Monensin vs. no treatment +1.9 –8.4 +6.4 +10.2* +8.5* +70.7*
DMSA vs. no treatment +8.1* –11.1 +13.8 +8.4* –1.0 +56.3*
Monensin + DMSA vs. DMSA  –2.1 +2.8 –1.2 –2.3 +2.2 +3.5
Monensin + DMSA vs.  +5.8 –8.6 –12.5 +5.8* +1.2 +61.7*
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +1.8 +5.8* +4.5 –5.3 –2.7 +6.8
Monensin vs. no treatment +8.7 –5.3* +3.3 +14.8* +10.0* +1.6
DMSA vs. no treatment +7.4 –4.7 –4.9 +5.5 –2.4 +10.1*
Monensin + DMSA vs. DMSA +0.3 –0.7 +15.9* –9.9* –2.8 +5.7
Monensin + DMSA vs.  +7.7 –5.3* +10.1* –5.0 –4.4 +16.4*
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded –23.7 –47.0 –4.9 –14.2 +11.6 +59.1*
Monensin vs. no treatment +0.5 +23.6 +7.9 +23.6* –11.7 +20.3
DMSA vs. no treatment +8.3 –18.6 +7.0 +9.4 –11.7 +27.8
Monensin + DMSA vs. DMSA –7.2 +6.2 –3.0 –8.0 –2.4 –23.4
Monensin + DMSA vs.  +0.5 –13.5 +3.8 +0.6 –2.2 –2.1
no treatment
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Abecause withdrawal of Pb alone is not very
effective at reducing Pb in these tissues,
because DMSA used alone is less effective in
these tissues than in some others, and because
the actions of Pb in heart, brain, and bone
account for significant aspects of Pb patho-
physiology. Thus, in heart, Pb accumulation
generates a set of effects that are analogous to
those produced by various forms of human
cardiac disease (Williams et al. 1983). In brain,
Pb effects manifest at low overall levels and
include cognitive impairment and reduced IQ
(Goyer 1993; Goyer et al. 1995; Rice 1996).
Bone Pb is problematic because this pool is
large and is the main source of Pb that reestab-
lishes an elevated blood concentration after
treatment by existing methods (Cory-Slechta
1988; Leggett 1993; O’Flaherty 1991, 1995;
O’Flaherty et al. 1998). Bone Pb can further-
more be mobilized together with Ca during
aging and pregnancy to produce toxic effects
even when there is no ongoing exposure to Pb
from the environment. Thus, it seems worth-
while to further explore the possibility of using
ionophores together with the traditional agents
in the clinical treatment of Pb intoxication.
Potential toxicity of the ionophore itself
must be considered when contemplating a
clinical application. There are no data available
on the toxic actions of monensin in humans;
however, the compound has long been admin-
istered to a variety of animal species that are
used to produce food in agriculture. This prac-
tice arose because monensin is an anticoccidial
agent, because it promotes growth, and
because it is easily administered in feed as was
done during this study (Ruff 1982; Shumard
and Callender 1968; Walker et al. 1980). The
level of 100 ppm used here is typical of that
used in agriculture and is well below the level
of 200 ppm where toxic actions are ﬁrst seen in
rats (Ruff 1982; Todd et al. 1984). To these
points we can now add that monensin plus
DMSA also produces no overt toxicity in rats
and has little effect on growth beyond that seen
with DMSA alone (Figure 15).
To further examine the potential for toxi-
city, we determined how tissue levels of other
elements changed during a period of Pb
administration and during our attempts to
remove it. Among the elements having a
physiologic role, no situation was found in
which the level of an element was markedly
decreased compared to that which existed
when Pb administration had been completed
and treatment was about to begin. The closest
we saw to this type of situation was with Co,
where levels tended to decline after removal of
Pb from the drinking water. The various
treatments used to remove Pb either had little
further effect or tended to restore Co to its
pretreatment value (Figure 3).
Likewise, we did not encounter examples in
which the levels of a physiologic element rose
markedly, compared with a pretreatment value,
as a result of any approach taken to remove Pb.
Cu, Fe, Mo, and Zn rose variously in some tis-
sues by as much as 50%, and there were a num-
ber of smaller changes (increases and decreases)
where statistical signiﬁcance could be demon-
strated (Figures 2–9). It is difﬁcult to say if any
of these are of consequence because data
describing the range of values found in normal
rats as a function of strain, diet, age, and so on,
are sparse. It also is not clear to what extent a
“normal value” may be decreased or increased
before giving rise to symptoms of deﬁciency or
overload toxicity, respectively.
Some further insight into these types of
questions is obtained by examining Table 1,
which shows tissue levels of physiologic ele-
ments in rats that had received Pb and levels
in rats that had not been exposed. We selected
data from unexposed rats reported by Naveh
et al. (1987) for comparison because the rats
they used were of a similar age and dietary his-
tory. As seen globally in Table 1, the size of
variations that were identified are similar to
those that arose during attempts to remove Pb
after it had accumulated. This supports our
Hamidinia et al.
490 VOLUME 114 | NUMBER 4 | April 2006 • Environmental Health Perspectives
Figure 11. (A) Fractional changes (+ SE) in tissue levels of Cd occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing val-
ues of other treatment groups. (B) Percent changes in mean values calculated
using the same data shown in (A).
Figure 12. (A) Fractional changes (+ SE) in tissue levels of Cr occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing values
of other treatment groups. Where data are missing, levels of Cr were too low to be
determined relative to the levels in blanks that arose as contaminants. (B) Percent
changes in mean values calculated using the same data shown in (A). ND, not
detected. 
*Statistically signiﬁcant (p < 0.05).
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Loaded No treatment Monensin DMSA DMSA + monensin
Cr
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +28.6 +17.5 +20.1 +3.6 +9.3 +14.3
Monensin vs. no treatment +28.4 +22.7 –36.9 +16.3 +15.4 –18.9
DMSA vs. no treatment +0.7 –10.2 +0.1 –5.8 –1.7 +0.9
Monensin + DMSA vs. DMSA +59.5 +5.0 +57.9 +2.0 +11.8 –13.3
Monensin + DMSA vs. +60.6 –5.7 +58.1 –3.9 +9.9 –12.6
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +14.8 –21.2 +13.3 –42.5* –63.1 ND
Monensin vs. no treatment +40.7 –17.9 –8.2 –13.6 –33.5 ND
DMSA vs. no treatment –81.4 +143 +41.0 –24.3 +370.9 ND
Monensin + DMSA vs. DMSA ND +96.9 –3.4 –4.1 –83.9 ND
Monensin + DMSA vs.  ND +379* +36.2 –27.4 –24.4 ND
no treatment
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view that the changes in physiologic element
levels that were seen during treatment for Pb
intoxication are of little consequence. This is
with the exception of Ca levels in kidney and
the levels of Cu and Mn in femur. There, the
same argument cannot be employed because
the normal values reported by Bogden and
colleagues (Naveh et al. 1987) fare about
10-fold higher than what we found after Pb
administration. These large variations may
reﬂect methodologic problems arising during
calibration or data analysis. We rechecked our
own methods upon seeing these differences
and note that our values are close to those
reported by others (Oishi et al. 2000; Seaborn
and Nielsen 2002a, 2002b). 
Another type of potential toxicity to con-
sider in contemplating the use of monensin to
treat Pb intoxication is the possibility that
other toxic elements present in the individual
might be perturbed in such way as to enhance
their toxicity, even though the toxicity from
Pb has been abated. Among the ﬁve toxic ele-
ments examined, we found scattered examples
where one or more of the treatment strategies
increased the level of a toxin in one or more of
the tissues (Figures 10–14). When observed,
these perturbations were sometimes much
larger than what was seen with physiologic 
elements (e.g., the 2- to 4-fold rise of Cr and Ni
in liver during treatment with monensin plus
DMSA), supporting the prospects for increased
toxicity. On the other hand, none of the non-
physiologic elements was being administered
beyond the trace quantities presumably present
in diet, water, and the general environment
provided to the rats. Accordingly, the levels of
these were very low (Table 1) even when they
had increased during attempts to removed Pb.
Thus, it is again difficult to judge if these
changes are meaningful in terms of toxicity
without conducting additional studies in which
the element of interest is purposely adminis-
tered. The same can be said for the scattered
examples where certain treatments for Pb intox-
ication decreased the level of another toxin
(e.g., Cr and Ni in brain and As in liver).
Interest is growing in the combined use of
multiple chelating agents for the treatment of
metal intoxication (Andersen and Aaseth 2002;
Kalia and Flora 2005; Link et al. 2001; Wu
et al. 2003), although the success of this
approach with Pb intoxication has been lim-
ited (Jones et al. 1997; Kachru et al. 2005;
Kostial et al. 1999). The question then arises:
How does monensin improve the effectiveness
of DMSA at removing Pb from various tissues
to the extent that is seen here? The multiple
chelator approach seems to work best when one
of the agents is fully water soluble and the other
has some hydrophobic character (Andersen and
Aaseth 2002; Giardina and Grady 2001). This
has been explained by the so-called relay
hypothesis, or shuttle hypothesis, which main-
tains that the more hydrophobic agent is able to
bind toxic cations that are located in compart-
ments not accessible to the hydrophilic com-
pound and can thereafter facilitate their
movement and transfer to the hydrophilic com-
pound. Once this has occurred, the hydrophilic
compound is excreted via the kidney, together
with the chelated cation. Monensin is highly
hydrophobic and is in fact a highly selective and
efﬁcient ionophore for Pb2+ (Hamidinia et al.
2002). It may then be particularly effective at
shuttling Pb2+ to DMSA located in blood or in
the interstitial ﬂuid compartment.
Additional factors to consider are illus-
trated in Figure 16 and relate to the fact that
monensin is an effective ionophore for sodium
ions (Na+) compared with potassium ions (K+)
(Henderson et al. 1969; Kinnally et al. 1991;
Pressman 1968). In addition, near a membrane
surface, the acid dissociation constant (pKa)
for monensin is 6.85, and the Na+ dissociation
constant (pKNa) is 5.00 (Hamidinia et al.
2002), whereas the in vivo concentrations of
Figure 13. (A) Fractional changes (+ SE) in tissue levels of Ni occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing val-
ues of other treatment groups. Where data are missing, levels of Ni were too low
to be determined relative to the levels in blanks that arose as contaminants.
(B) Percent changes in mean values calculated using the same data shown in (A).
ND, not detected. 
*Statistically signiﬁcant (p < 0.05).
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Figure 14. (A) Fractional changes (+ SE) in tissue levels of Sr occurring during
treatment for Pb intoxication. For details, see “Materials and Methods” and
Table 1; values for the Pb-loaded group were set to 1.0 to aid in normalizing
values of other treatment groups. (B) Percent changes in mean values calcu-
lated using the same data shown in (A). 
*Statistically signiﬁcant (p < 0.05). 
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Loaded No treatment Monensin DMSA DMSA + monensin
Sr
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +63.3 +38.1 –5.5 +28.2 –51.1 ND
Monensin vs. no treatment +48.6 +168.9 –58.9 –26.8 –22.2 –42.2
DMSA vs. no treatment +37.1 –40.5 –67.0* –31.7 –35.4 –74.6
Monensin + DMSA vs. DMSA +3.8 +458* +260* +61.9* +2.9 +515.8
Monensin + DMSA vs.  +42.3 +232* +19.0 +10.6 –33.6 +56.6
no treatment
Tissue (percent change)
Comparison Kidney Liver Muscle Heart Brain Femur
No treatment vs. loaded +162* +31.5 –37.1 +136* –15.0 +12.7
Monensin vs. no treatment +10.4 +1.7 +9.7 +21.6 +17.1 –0.3
DMSA vs. no treatment +29.2 –9.7 –10.3 +39.3 +35.6 +0.3
Monensin + DMSA vs. DMSA –31.9* +13.5 +10.8 –49.3* –12.6 +2.0
Monensin + DMSA vs. –12.0 +2.5 –0.6 –29.4 +18.5 +2.3
no treatment
B
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Ahydrogen ions (H+) and Na+ in extracellular
volumes are about 10–7 M and 10–3 M,
respectively. The pK values were obtained in
solutions of 80% methanol in water, an envi-
ronment that mimics a membrane–water
interface in terms of polarity (Pfeiffer et al.
1983; Taylor et al. 1985, 1993). Furthermore,
at physiologic pH, it appears that the predom-
inant species by which monensin transports
Pb2+ is the mixed complex monensin·Pb·OH
(Hamidinia et al. 2002). Thus, when acting to
deliver intracellular Pb2+ to extracellular
DMSA, it is probable that the compound
enters cells as the species monensin·Na, leaves
as the mixed complex, and so in effect
catalyzes an exchange of extracellular Na+ for
intracellular PbOH+ (equivalent to exchanging
an extracellular Na+ and an H+ for an intra-
cellular Pb2+) (Figure 16). Given that the
external/internal Na+ concentration gradient is
maintained by Na,K-ATPase, the presence of
monensin partially couples the release of intra-
cellular Pb2+ to ATP hydrolysis, giving a direc-
tion and a driving force to the process. This
may also help explain why the presence of
monensin enhances the effectiveness of DMSA
at removing Pb. However, it should also be
pointed out that monensin may act in a more
indirect way to enhance the action of DMSA.
One possibility relates to the depletion of Pb
from bone, where monensin might increase the
rate of bone turnover. Were that to occur,
access of Pb to DMSA would possibly be
increased without a requirement for direct
Pb2+ transport mediated by the ionophore.
A final point arises upon comparing an
aspect of the present data with those from a
previous study in which monensin alone was
administered to Pb-intoxicated rats (Hamidinia
et al. 2002). The earlier study showed that
monensin alone accelerated the removal of Pb
from several tissues, compared with no treat-
ment, whereas in the present study this was
seen only in heart tissue (Figure 1). In the pre-
sent study, Pb was released more efficiently
under the no-treatment condition than was
reported earlier (Hamidinia et al. 2002), even
though the design of both studies was very
similar. These differences related to how the
rats were housed: during the earlier study
(Hamidinia et al. 2002), they were housed
individually and in metabolic cages (i.e., stand-
ing on metal gratings), which are both consid-
ered to be stressful circumstances; in the
present study rats were housed in pairs, in plas-
tic cages containing normal bedding. When
viewed collectively, these considerations suggest
that the mechanism(s) that remove Pb under
no-treatment conditions are less efficient in
stressed rats and that monensin used alone is
more efﬁcient when organ Pb levels are higher.
The later point is of interest here because it
implies that monensin alone may be even more
effective at higher levels of Pb intoxication and
that other Pb ionophores having a higher afﬁn-
ity for Pb may also be more effective. These
possibilities can be tested experimentally and
are under investigation.
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Figure 16. Potential relationships between the trans-
port of Na+ and Pb2+. The two parallel curved lines
represent a section of plasma membrane bounding
a cell that contains Pb2+. To the left and right of
these lines are the extra- and intracellular compart-
ments, respectively. Pi indicates inorganic phos-
phate; “+” and “–” indicate the membrane potential
orientation inside and outside the vesicle. (A) The
formation of an electrochemical Na+ gradient
across this membrane through action of Na,K-
ATPase. (B) Monensin (Mon) transports Na+ down
the Na+ gradient. (C) Pb2+ is transported out. The net
result of processes occurring in (B) and (C) is the
electroneutral exchange of an intracellular Pb2+ and
an OH– for an external Na+.
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